Peptide-based vaccines for cancer immunotherapy (Q35681508)

9 August 2017

1 reference

title

Peptide-based vaccines for cancer immunotherapy (English)

1 reference

9 August 2017

1 reference

4

W Martin Kast

1 reference

9 August 2017

Joeli A Brinkman

1

1 reference

9 August 2017

Steven C Fausch

series ordinal

2

1 reference

9 August 2017

Jeffrey S Weber

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Expert Opinion on Biological Therapy

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

181-198

1 reference

Current developments in cancer vaccines and cellular immunotherapy

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Ins and outs of clinical trials with peptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Recent progress in tumour vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Vaccines for papillomavirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Structure and transcription of human papillomavirus sequences in cervical carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Carcinoembryonic antigen-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

Quantitating cellular immune responses to cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.2.181

21 January 2018

Identifiers

DOI

10.1517/14712598.4.2.181

1 reference

release_fgxs45xh5jerzlgslnnyiu7s34

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fgxs45xh5jerzlgslnnyiu7s34

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference